ArticleTheranostics2018
A Transferrin-Conjugated Hollow Nanoplatform for Redox-Controlled and Targeted Chemotherapy of Tumor with Reduced Inflammatory Reactions.
Erratum issuedAbstract read
In one paragraph
Article in Theranostics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Molecular Engineering of Aptamers for Glioblastoma Therapy: From Simple Antagonists to AI-Driven Approaches, a Narrative Review.International journal of molecular sciences · 2026Review
- Smart Nanoformulations for Oncology: A Review on Overcoming Biological Barriers with Active Targeting, Stimuli-Responsive, and Controlled Release for Effective Drug Delivery.Pharmaceutics · 2026Review
- HACS applied bio materials · 2025Article
- Application of Nanomedicine in Tumor Targeting Inflammatory Pathway.Current medicinal chemistry · 2025Review
- Brain-targeted drug delivery - nanovesicles directed to specific brain cells by brain-targeting ligands.Journal of nanobiotechnology · 2024Review
- Mesoporous Silica-Based Nanoplatforms Are Theranostic Agents for the Treatment of Inflammatory Disorders.Pharmaceutics · 2023Review
- Application of aptamer functionalized nanomaterials in targeting therapeutics of typical tumors.Frontiers in bioengineering and biotechnology · 2023Review
- Receptor-mediated targeted drug delivery systems for treatment of inflammatory bowel disease: Opportunities and emerging strategies.Acta pharmaceutica Sinica. B · 2021Review
- Redox-Responsive Mesoporous Silica Nanoparticles for Cancer Treatment: Recent Updates.Nanomaterials (Basel, Switzerland) · 2021Review
- Biosafety of mesoporous silica nanoparticles: a combined experimental and literature study.Journal of materials science. Materials in medicine · 2021Article
- Assessing Suitability of Co@Au Core/Shell Nanoparticle Geometry for Improved Theranostics in Colon Carcinoma.Nanomaterials (Basel, Switzerland) · 2021Article
- Transferrin-Decorated Protein-Lipid Hybrid Nanoparticle Efficiently Delivers Cisplatin and Docetaxel for Targeted Lung Cancer Treatment.Drug design, development and therapy · 2021Article
- Mesoporous Silica Nanoparticles for Targeting Subcellular Organelles.International journal of molecular sciences · 2020Review
- Aptamer-Based In Vivo Therapeutic Targeting of Glioblastoma.Molecules (Basel, Switzerland) · 2020Review
- Influence of the Surface Functionalization on the Fate and Performance of Mesoporous Silica Nanoparticles.Nanomaterials (Basel, Switzerland) · 2020Review
- Therapeutic Nanoparticles and Their Targeted Delivery Applications.Molecules (Basel, Switzerland) · 2020Review
- Bacterial magnetosomes loaded with doxorubicin and transferrin improve targeted therapy of hepatocellular carcinoma.Nanotheranostics · 2019Article
- Co-Delivery of Curcumin and Paclitaxel by "Core-Shell" Targeting Amphiphilic Copolymer to Reverse Resistance in the Treatment of Ovarian Cancer.International journal of nanomedicine · 2019Article
- Exosomes in Head and Neck Squamous Cell Carcinoma.Frontiers in oncology · 2019Review
- Functional biomimetic nanoparticles for drug delivery and theranostic applications in cancer treatment.Science and technology of advanced materials · 2018Review
Corrections and comments
- Erratum issued
Authors and funding
12 authors.
Jun ZhouSchool of Life Science, Chongqing University, Chongqing 400044, P. R. China.
Menghuan LiSchool of Life Science, Chongqing University, Chongqing 400044, P. R. China.
Wei Qi LimDivision of Chemistry and Biological Chemistry, School of Physical and Mathematical Sciences, Nanyang Technological University, 21 Nanyang Link, Singapore 637371.
Zhong LuoSchool of Life Science, Chongqing University, Chongqing 400044, P. R. China.
Soo Zeng Fiona PhuaDivision of Chemistry and Biological Chemistry, School of Physical and Mathematical Sciences, Nanyang Technological University, 21 Nanyang Link, Singapore 637371.
Runlan HuoSchool of Life Science, Chongqing University, Chongqing 400044, P. R. China.
Liqi LiDepartment of General Surgery, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, China.
Ke LiKey Laboratory of Biorheological Science and Technology, Ministry of Education, Chongqing University, Chongqing 400044, P. R. China.
Liangliang DaiKey Laboratory of Biorheological Science and Technology, Ministry of Education, Chongqing University, Chongqing 400044, P. R. China.
Junjie LiuKey Laboratory of Biorheological Science and Technology, Ministry of Education, Chongqing University, Chongqing 400044, P. R. China.
Kaiyong CaiKey Laboratory of Biorheological Science and Technology, Ministry of Education, Chongqing University, Chongqing 400044, P. R. China.
Yanli ZhaoDivision of Chemistry and Biological Chemistry, School of Physical and Mathematical Sciences, Nanyang Technological University, 21 Nanyang Link, Singapore 637371.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
AnimalsAntineoplastic AgentsCell Line, TumorDoxorubicinDrug CarriersDrug Delivery SystemsInflammationMiceNanoparticlesOxidation-ReductionPorosityRAW 264.7 CellsSilicon DioxideTransferrinAntineoplastic AgentsDoxorubicinDrug CarriersSilicon DioxideTransferrinattenuation of inflammationhollow mesoporous silica nanoparticlesredox-responsive releasetargeted chemotherapytransferrin conjugation.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.